MedTrace Logo

Validation of SMS Protocol for HCC Screening in High-risk Patients

NCT05429190 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 470

Last updated 2023-11-29

No results posted yet for this study

Summary

The investigators will assess implementation of the proposed SMS protocol as a surveillance tool in patients at high risk of developing HCC in a prospective multicenter study.

Conditions

Interventions

RADIATION

Short MRI surveillance (SMS) protocol

Bi-annual, non-contrast agents, MRI screening consisting of Diffusion Weighted Imaging (b-values of 50 and 800 s/mm2), T2-weighted imaging and T1-weighted in- and out-of-phase imaging

RADIATION

Bi-annual ultrasonography screening

Bi-annual ultrasonography for screening of HCC in high-risk patients

Sponsors & Collaborators

Principal Investigators

  • Prof. Dr. de Man · Erasmus Medical Center

  • Dr. Takkenberg · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  • Prof. Dr. Uyl-de Groot · Erasmus School of Health Policy & Management Rotterdam

  • Prof. Dr. IJzermans · Erasmus Medical Center

  • Dr. Bos · Erasmus Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-07
Primary Completion
2026-06-01
Completion
2026-06-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05429190 on ClinicalTrials.gov